Hypertension Is an Independent Predictor of Multivessel Coronary Artery Disease in Young Adults with Acute Coronary Syndrome

Junhua Ge, Jian Li, Haichu Yu, and Bo Hou

Department of Cardiology, The Affiliated Hospital of Qingdao University, Jiangsu Road 16, 266000 Qingdao, Shandong, China

Correspondence should be addressed to Junhua Ge; gejunhua198110@163.com

Received 19 August 2018; Revised 18 October 2018; Accepted 1 November 2018; Published 13 November 2018

Background. Risk factors of multivessel coronary artery disease (CAD) among young acute coronary syndrome (ACS) patients remain elusive now. Methods. This retrospective study analyzed data from 187 consecutive young (age ≤45 years) ACS patients (75 STEMI, 30 NSTEMI, and 72 unstable angina) hospitalized in our hospital from January 2012 to December 2016. Thirty-six young male patients with normal coronary angiography (CAG) findings (no-CAD), who underwent CAG due to suspected chest pain in this period, served as control group. There were 83 patients with single-vessel disease (SVD) and 104 patients with multiple-vessel disease (MVD) among ACS patients. Patients were followed up for a mean of 267±124 days by clinical visit or telephone calls. Results. All included patients were male. Prevalence of hypertension (57.2% vs. 30.6%, p=0.002) and smoking (70.6% vs. 52.8%, p=0.049) was significantly higher in ACS patients than in no-CAD patients. Prevalence of hypertension (72.1% vs. 38.6%, p<0.001) and body mass index (BMI) were significantly higher in MVD group than in SVD group. Multivariable analysis revealed that hypertension was an independent risk factor for MVD after adjustment for age, gender, BMI, smoking, family history of premature CAD, hyperlipidemia, left ventricular ejection fraction, and brain natriuretic peptide (odds ratio=3.71, 95% confidence interval=1.84-7.46, p<0.001). Rate of major adverse cardiovascular events (MACE) during follow-up (20.2% vs. 4.8%) was significantly higher in MVD group compared with SVD group. Conclusions. Hypertension is an independent predictor of MVD and MVD is associated with increased MACE rate compared to SVD in young ACS patients during the short-term follow-up.

1. Introduction

Risk factor profiles, clinical presentations, and prognosis might differ between young patients with acute coronary syndrome (ACS) and elderly ACS patients [1–4]. Previous studies showed that the prevalence of ACS among population less than 45 years of age (young ACS) ranged from 2% to 10% [4–6]. Young ACS cases were more prevalent among the Malays (49.8%), followed by Indians (24.4%), Chinese (21.8%), and other races (4.1%) [2]. Risk factors of ACS are age-dependent. Jamil et al. reported that prevalence of smoking (79.2% vs. 66.2%, p<0.001) was significantly higher, while prevalence of diabetes (12.1% vs. 25.6%, p<0.001), hypertension (34.4% vs. 57.4%, p<0.001), and hyperlipidemia (39.7% vs. 50.1%, p<0.001) was significantly lower in young ACS patients compared to elderly (>55 years old) ACS patients [7]. Smoking was identified as one of the major risk factors of ACS in young adults [2].

Several randomized controlled trials hinted that multi-vessel coronary artery disease (CAD) may occur in up to 50% of all CAD patients [8, 9]. Previous studies also demonstrated that patients with multiple-vessel disease (MVD) faced substantially increased risks of mortality and major adverse cardiac events, such as reinfarction or need for urgent revascularization after successful primary percutaneous coronary intervention (PCI) [10, 11]. It is known that incidence of diabetes, advanced age, impaired left ventricular function, and history of stroke are usually high in MVD patients [12, 13].

At present, there are only scanty reports on the prevalence and risk factors as well as outcome of MVD in young ACS patients. In the present study, we compared the risk factors
and short-term outcome between young ACS patients with single-vessel disease (SVD) or MVD.

2. Methods

2.1. Study Population. In total, 187 consecutive young male adult (aged ≤45 years) ACS patients hospitalized in our department between January 2012 and December 2016 were enrolled in this study. Thirty-six young male patients with normal coronary angiography (CAG) findings (no-CAD), who underwent CAG due to suspected chest pain in this period, served as control group. The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee. Written informed consent was obtained from all patients. ACS refers to any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). UA was defined as angina pectoris or equivalent ischemic discomfort with at least one of three features: (1) it occurs at rest (or with minimal exertion), usually lasting >10 minutes; (2) it is severe and of new onset (i.e., within the prior 4-6 weeks); (3) it occurs with a crescendo pattern (i.e., distinctly more severe, prolonged, or frequent than previously) [14]. STEMI was defined as the presence of typical chest pain accompanying symptoms for a duration of at least 30 minutes but <12 hours in the presence of ST-segment elevation ≥1 mm in at least 2 contiguous leads, or new or undetermined duration of left bundle branch block in association with elevated cardiac enzymes [creatine kinase myocardial band (CK-MB) and Troponin I] [15]. NSTEMI was defined as ECG ST-segment depression or prominent T-wave inversion and/or positive biomarkers of necrosis in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or angina equivalent) [15]. SVD referred single-vessel lumen stenosis ≥50%, luminal stenosis of left main coronary artery greater than 50%; MVD referred at least two main arteries with stenosis of vessel lumen ≥50%, luminal stenosis of left main coronary artery >50% by CAG [16, 17]. The degree of coronary artery stenosis was visually rated by 2 experienced interventional cardiologists. Hypertension was defined as a history of systolic blood pressure (SBP) ≥140 mmHg or a diastolic blood pressure (DBP) ≥90 mmHg or documented hypertension on at least two occasions in outpatient clinics or known hypertension under antihypertensive medication regardless of the current blood pressure [18]. Smoking was classified into three categories: never smokers, ex-smokers (those who had smoked regularly but had stopped smoking at least six months before the survey), and current smokers. We used the 2016 American Diabetes Association (ADA) guidelines for the diagnosis of diabetes [19], and the 2013 ACC/AHA guidelines management of dyslipidemias for the diagnosis of hyperlipidemia [20].

Procedural factors recorded included the infract-related artery, number of diseased vessels, number of stents, and thrombus aspiration (TA) device use. Apart from the patient's baseline characteristics (ECG recordings, age, sex, hypertension, smoking status, hyperlipidemia, and family history of premature CAD and history of previous ACS), the following biochemical indices were analyzed: CK-MB, complete lipid profile, blood cell count, urea, creatinine, brain natriuretic peptide (BNP), and hepatic aminotransferases. Echocardiography was performed in all patients after CAG and/or PCI. All patients were followed up and treated according to the current guidelines of ACS [21].

2.2. Outcomes. The primary clinical outcome was major adverse cardiac events (MACE), defined as all-cause mortality, recurrent MI, stroke, coronary artery bypass graft (CABG), and repeat PCI during the follow-up period. Secondary clinical outcomes included inhospital and 30 days all-cause mortality rate. The follow-up was made by clinical visit or telephone calls.

2.3. Statistical Analysis. Continuous variables are expressed as mean ± SD and categorical variables as number (percent). The data were analyzed by homogeneity of variances test. Continuous data with normal distribution were assessed by Student's t-test or one-way ANOVA with post hoc test (Bonferroni) as indicated. Nonnormal distribution data were tested by two-tailed Mann–Whitney U test or Kruskal-Wallis nonparametric test as indicated. Categorical data were compared across groups using Chi-square test or Fisher's exact test as appropriate. The associations of hypertension with MVD were evaluated using univariate and multivariate binary logistic regression models. Odds ratio (OR) and 95% confidence interval (CI) for MVD were calculated. In the multivariate models, age, gender, body mass index (BMI), hyperlipidemia, smoking, and family history of premature coronary artery disease, albumin, BNP, and left ventricular ejection fraction (LVEF) were included as covariates. P value <0.05 (two-tailed test) was considered statistically significant. The statistical analysis was performed using the SPSS statistical software, version 23.0 (IBM SPSS Statistics, Chicago, USA).

3. Results

3.1. Patient Characteristics. Table 1 shows the patient characteristics. All subjects are male. The median age of the MVD group was significantly older than that of control group (p=0.024). Hypertension was diagnosed in 118 out of 233 subjects (53%). Forty-four hypertensive patients received antihypertensive medication and the rest received no anti-hypertensive medication, and blood pressure was controlled in 19 out of 44 (43.2%) treated hypertensive patients. Hypertension and smoking were more frequent in the ACS group compared with no-CAD group (57.2% vs. 30.6%, p=0.002, and 70.6% vs. 52.8%, p=0.049, respectively). Regional wall motion abnormality was present in 50.8% of ACS patients. The prevalence of hypertension was significantly higher in MVD group than in SVD group (72.1% vs. 38.6%, p<0.001).

Table 2 presents the laboratory findings. WBC count, CK-MB, myoglobin, and high-sensitivity troponin I levels were significantly higher in ACS group than in no-CAD group and were similar between SVD and MVD groups. Prevalence
Table 1: Clinical characteristics.

|                | No-CAD          | SVD             | ACS             | MVD             |
|----------------|-----------------|-----------------|-----------------|-----------------|
|                | N=36            | N=83            | N=104           |                 |
| Age (years)    | 41 (37-43)      | 40 (38-44)      | 42 (40-45)      |                 |
| Gender (M/F)   | 36/0            | 83/0            | 104/0           |                 |
| BMI (kg/m²)    | 26.8±4.8        | 26.2±3.5        | 27.8±3.6        |                 |
| Baseline SBP (mmHg) | 131.5±14.2    | 127.0±20.1      | 128.6±19.4      |                 |
| Baseline DBP (mmHg) | 81.6±9.0        | 78.9±13.5       | 80.3±15.1       |                 |
| HR (beats/min) | 70.6±15.4       | 70.7±12.9       | 72.0±14.4       |                 |
| Hypertension   | 11 (30.6)       | 32 (38.6)       | 75 (72.1)*      |                 |
| Duration (year) | 5.7±3.8         | 4.8±4.5         | 6.9±5.4         |                 |
| Family history | 6 (16.9)        | 11 (13.3)       | 21 (20.2)       |                 |
| Smoking        | 19 (52.8)       | 64 (77.1)*      | 68 (65.4)*      |                 |
| Duration (year) | 16.5±7.9        | 17.9±6.6        | 18.9±7.9        |                 |
| Consumption (cigarettes/day) | 19.7±12.7    | 22.3±10.5       | 24.9±13.3       |                 |
| Alcohol use    | 6 (16.7)        | 14 (16.9)       | 13 (12.5)       |                 |
| Duration (year) | 12.5 (10-20)    | 20 (17.5-20)    | 20 (10-20)      |                 |
| Consumption (g/day) | 64 (20-103)  | 75 (27-150)     | 20 (20-75)      |                 |
| Family history of premature CAD | 5 (13.9) | 15 (18.1)       | 29 (27.9)       |                 |
| Diabetes mellitus | 0             | 0               | 0               |                 |
| Hyperlipidemia | 0               | 3 (3.6)         | 3 (2.9)         |                 |
| Echocardiography|                |                 |                 |                 |
| LVEF (%)       | 62.6±2.7        | 59.7±6.7        | 58.2±6.4*       |                 |
| Regional wall motion abnormality [n (%)] | 0 | 41 (49.4)* | 53 (52.0)* |            |

p<0.05 vs. no-CAD group; ¹p<0.05 vs. SVD group. ACS: acute coronary syndrome; BMI: body mass index; CAD: coronary artery disease; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; MVD: multivessel coronary artery disease; SBP: systolic blood pressure; SVD: single-vessel disease.

3.2. Procedural and Coronary Artery Involvement Characteristics. Angiographic and procedural characteristics of the study population were listed in Table 3. The prevalences of left anterior descending artery (LAD), circumflex artery (LCX), and right coronary artery (RCA) lesion in the MVD group were significantly higher than in the SVD group. As shown in Figure 1, hypertension is related to higher prevalence of LAD, LCX, and RCA lesion. Additionally, prevalence of LAD-related stenosis (75.4%) was significantly more common than that of RCA (63.6%) and LCX-related stenosis (44.9%) in patients with hypertension (both p<0.001, Figure 1).

3.3. Hypertension and Smoking Are Independent Risk Factors for ACS in Young Adults. Table 4 shows the binary logistic regression results for ACS. Hypertension served as an independent risk factor for ACS (unadjusted OR 3.16, 95% CI 1.48-7.88, p=0.003), after adjustment for age, gender, and BMI (OR 2.91, 95% CI 1.30-6.52, p=0.009) and after adjustment for age, gender, BMI, smoking, family history of premature coronary artery disease, and hyperlipidemia (OR 3.42, 95% CI 1.48-7.88, p<0.001). Smoking is also an independent risk factor for ACS (unadjusted OR 2.04, 95% CI 0.99-4.19, p=0.052), after adjustment for age, gender,
Table 2: Laboratory findings.

|               | No-CAD N=36 | SVD N=83 | ACS N=104 |
|---------------|-------------|----------|-----------|
| WBC count (10^9/L) | 6.2 (5.3-7.5) | 11.7 (6.8-14.6)* | 12.3 (6.6-14.6)* |
| Hemoglobin (g/L) | 151.5±11.4  | 149.4±13.9 | 153.2±16.5 |
| Platelet count (10^9/L) | 209.7±56.7  | 217.9±45.6  | 221.5±50.7 |
| CK-MB (ng/mL) | 1.12 (0.9-2.7) | 30 (2.3-52.0)* | 31 (2.4-56.0)* |
| Myoglobin (ng/mL) | 34.0 (23.5-53.0) | 439.7 (35.0-500) | 426.5 (35.3-558.2)* |
| High-sensitivity troponin I (ng/mL) | 0.08 (0.05-0.29) | 5.2 (0.1-6.8)* | 5.2 (0.3-8.6)* |
| BNP (pg/ml) | 17.3 (8.7-40.6) | 40 (17.3-82.3)* | 60 (26.2-127.5)* |
| Total protein (g/L) | 68.2±6.4  | 63.0±7.8*  | 62.9±6.6* |
| Albumin (g/L) | 24.7±4.5  | 25.6±3.8  | 25.6±3.7 |
| Globulin (g/L) | 1.7±0.3  | 1.8±2.7  | 1.6±0.4 |
| TG (mmol/L) | 1.3 (0.9-1.8) | 1.5 (1.2-2.0) | 2.5 (1.4-2.5)* |
| TC (mmol/L) | 4.4±1.2  | 4.5±1.3  | 4.7±1.3 |
| HDL-C (mmol/L) | 1.2±0.3  | 1.1±0.3  | 1.1±0.2 |
| LDL-C (mmol/L) | 2.4±1.0  | 2.8±1.0  | 2.8±1.0 |
| GLU (mmol/L) | 5.1±0.8  | 5.4±1.4  | 5.5±1.2 |
| BUN (mmol/L) | 5.3±1.0  | 5.1±1.3  | 5.1±1.4 |
| SCR (µmol/L) | 89.2±14.1 | 87.5±17.2 | 90.7±15.5 |
| Uric Acid (µmol/L) | 331.8±127.5 | 349.6±115.9 | 370.9±93.6 |

* p<0.05 vs. no-CAD group, † p<0.05 vs. SVD group. ACS: acute coronary syndrome; A/G: albumin to globulin ratio; BNP: brain natriuretic peptide; BUN: blood urea nitrogen; CAD: coronary artery disease; CK-MB: creatine kinase myocardial band; GLU: glucose; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MVD: multivessel coronary artery disease; RBC: red blood cell; SCR: serum creatinine; SVD: single vessel disease; TC: total cholesterol; TG: triglyceride; WBC: white blood cell.

Table 3: Angiographic and procedural characteristics.

|               | No-CAD N=36 | SVD N=83 | ACS N=104 |
|---------------|-------------|----------|-----------|
| Stenosis-related artery LM [n (%)] | 0 | 1 (1.2) | 3 (2.9) |
| Stenosis-related artery LAD [n (%)] | 0 | 40 (48.2)* | 96 (92.3)*† |
| Stenosis-related artery LCX [n (%)] | 0 | 11 (13.3)* | 71 (68.9)*† |
| Stenosis-related artery RCA [n (%)] | 0 | 31 (37.3)* | 90 (86.5)*† |
| TA device used [n (%)] | 0 | 6 (7.2) | 7 (6.7) |
| Number of stents | 0 | 0.8±0.7* | 1.1±0.9*† |
| Prior MI [n (%)] | 0 | 0 | 0 |
| Prior PCI [n (%)] | 0 | 0 | 0 |
| Prior CABG [n (%)] | 0 | 0 | 0 |

* p<0.05 vs. no-CAD group, † p<0.05 vs. SVD group. ACS: acute coronary syndrome; CABG: coronary artery bypass graft; CAD: coronary artery disease; LAD: left anterior descending artery; LCX: circumflex artery; LM: left main; MVD: multivessel coronary artery disease; PCI: percutaneous coronary intervention; RCA: right coronary artery; SVD: single-vessel disease; TA: thrombus aspiration.

and BMI (OR 2.36, 95% CI 1.12-4.96, p=0.024) and after adjustment for age, gender, BMI, hypertension, family history of premature coronary artery disease, and hyperlipidemia (OR 2.49, 95% CI 1.16-5.34, p=0.019). BNP and LVEF were associated with the prognosis of ACS patients. After adding these two indexes as adjusted cofounders, the predicting efficacy of hypertension and smoking weakened to the borderline significant level: hypertension (p=0.077) and smoking (p=0.071).

3.4. Hypertension Is an Independent Risk Factor for MVD in Young ACS Patients. Table 5 shows the binary logistic regression results for MVD. Hypertension remained as an independent risk factor for MVD (unadjusted OR 4.20, 95% CI 2.27-7.77, p<0.001) after adjustment for age, gender, and BMI (OR 3.59, 95% CI 1.89-6.83, p<0.001); after adjustment for age, gender, BMI, smoking, family history of premature coronary artery disease and hyperlipidemia (OR 3.63, 95% CI 1.88-7.01, p<0.001); after adjustment for age, gender, BMI,
Table 4: Hypertension and smoking for prediction of acute coronary syndrome based on multivariable logistic regression models (n=223).

|                    | Unadjusted OR | 95% CI       | p value |
|--------------------|---------------|--------------|---------|
| Hypertension       | 3.16          | 1.48-6.78    | 0.003   |
| Smoking            | 2.04          | 0.99-4.19    | 0.052   |
| Adjusted OR        |               |              |         |
| Hypertension       | 2.91          | 1.30-6.52    | 0.009   |
| (Adjusted for age, gender, and BMI) |               |              |         |
| Hypertension       | 3.42          | 1.48-7.88    | <0.001  |
| (Adjusted for age, gender, BMI, hyperlipidemia, smoking, and family history of premature CAD) |               |              |         |
| Hypertension       | 2.94          | 0.89-9.73    | 0.077   |
| (Adjusted for age, gender, BMI, hyperlipidemia, smoking, family history of premature CAD, BNP, and LVEF) |               |              |         |
| Smoking            | 2.36          | 1.12-4.96    | 0.024   |
| (Adjusted for age, gender, and BMI) |               |              |         |
| Smoking            | 2.49          | 1.16-5.34    | 0.019   |
| (Adjusted for age, gender, BMI, hyperlipidemia, hypertension, and family history of premature CAD) |               |              |         |
| Smoking            | 2.72          | 0.92-8.07    | 0.071   |
| (Adjusted for age, gender, BMI, hyperlipidemia, hypertension, family history of premature CAD, BNP, and LVEF) |               |              |         |

BMI: body mass index; BNP: brain natriuretic peptide; CAD: coronary artery disease; CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio.
Table 5: Hypertension for prediction of multivessel coronary artery disease based on multivariable logistic regression models (n=187).

| Hypertension                          | Unadjusted OR | 95% CI       | p value |
|---------------------------------------|---------------|--------------|---------|
| Hypertension                          | 4.20          | 2.27-7.77    | <0.001  |
| (Adjusted for age, gender, and BMI)   |               |              |         |
| Hypertension                          | 3.59          | 1.89-6.83    | <0.001  |
| (Adjusted for age, gender, BMI, hyperlipidemia, smoking, and family history of premature CAD) | |              |         |
| Hypertension                          | 3.63          | 1.88-7.01    | <0.001  |
| (Adjusted for age, gender, BMI, albumin, BNP, and LVEF) | |              |         |

BMI: body mass index; BNP: brain natriuretic peptide; CAD: coronary artery disease; CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio.

Figure 2: Scatter plot of SBP and DBP among patients with no-CAD, SVD, and MVD. Note that incidence of hypertension [SBP > 150 mmHg (y-axis) and/or DBP > 90 mmHg (x-axis)] was significantly higher in MVD patients (75 out of 104, 72.1%) than in patients with SVD (34 out of 83, 40.5%) and in no-CAD patients (16 out of 37, 44.4%). DBP: diastolic blood pressure; MVD: multivessel coronary artery disease; no-CAD: no coronary artery disease; SBP: systolic blood pressure; SVD: single-vessel disease.

4. Discussion

To the best of our knowledge, this is the first study to evaluate the association between hypertension and MVD in young ACS patients. The major findings of the present study are as follows: Firstly, the presence of hypertension, but not smoking, is an independent predictor of MVD in young patients with ACS. Secondly, the rate of MACE was significantly higher in MVD group compared with SVD group during the 267±124 days of follow-up. Our results thus highlight the role of hypertension in the pathogenesis of MVD in young ACS patients, suggesting that hypertension control serves as an important strategy for the prevention and treatment of MVD in young ACS patients.

4.1. Risk Factors of ACS in Young Adults.

Previous investigations have reported that young ACS patients have a different risk factor profile compared with elderly ACS patients [7, 22–24]. Hypertension is a known important risk factor for the development of coronary artery disease [25]. The impact of smoking on elderly patients with coronary artery disease is well established, while conflicting results existed on the impact of smoking in young adults with coronary artery disease [25, 26]. It was reported that the prevalence of hypertension was 25% in young coronary artery disease patients as compared to 13% in young non-coronary artery disease subjects and the prevalence of hypertension was much higher in elderly individuals with coronary artery disease than in young coronary artery disease patients [27]. In this study, we showed that prevalence of hypertension in young ACS patients was higher than previously reported and hypertension, together with smoking, served as independent risk factors for ACS. Conflicting results were reported on the impact of diabetes in young ACS patients [25, 26]. There is
no diabetic patients in our real-world-derived patient cohort, there was also no young female ACS patients in our cohort, and the contribution of diabetes and gender effect could thus not be evaluated based on our data. Our study found that hypertension and smoking are the major risk factors of young male ACS patients, while hyperlipidemia and family history of coronary artery disease played only a negligible role in young male ACS patients based on data from this patient cohort.

4.2. Association between Hypertension and MVD in Young ACS Patients. The association between hypertension and MVD in young ACS patients remains controversial. Sukhija et al. observed higher prevalence of MVD in hypertensive patients compared to nonhypertensives [27]. However, Zand Parsa et al. did not find any relationship between hypertension and MVD [28]. Our results indicated a strong association between hypertension and MVD in young male ACS patients, in that the prevalence of hypertension is as high as 72.1% in MVD group compared to 38.6% in SVD group (p<0.001, Figure 2). Moreover, results of the ordinal logistic regression model for MVD revealed that hypertension was a significant independent risk factor for MVD after adjustment for smoking, BMI, family history of premature CAD, BNP, LVEF, and hyperlipidemia in young male ACS patients. In addition, our results suggested that SBP >150mmHg and/or DBP >90mmHg as the cut-off value could fairly predict the presence of MVD (sensitivity of 72% and specificity of 58%) in young male ACS patients.

4.3. Smoking and Prevalence of ACS and MVD in Young Adults. Previous studies have demonstrated that smoking is the most important risk factor associated with the severity of coronary artery disease and is significantly linked with increased risk of coronary plaque vulnerability, myocardial infarction, and cardiovascular death [29, 30]. Previous report showed that the prevalence of smoking in younger coronary infarction, and cardiovascular death [29, 30]. Previous report showed that the prevalence of smoking in younger coronary artery disease individuals (<45 years of age) ranged from 60% to 90% as compared to 24% to 56% in subjects aged 45 years and over [31, 32]. In addition, smoking served as the most important modifiable risk factor for young adult patients with ACS [24]. Our data are in accordance with previous findings in that the prevalence of smoking was high (70.6%) in young ACS patients and smoking was an independent predictor of ACS in young adults [OR: 2.49 (95% CI 1.16-5.34)] after adjustment for age, gender, BMI, hyperlipidemia, hypertension, and family history of premature CAD (Table 4). However, smoking was not an independent risk factor after adding BNP and LVEF as adjusted cofounders for ACS, and smoking was not an independent risk factor for MVD.

4.4. Outcome of Young MVD Patients. Previous studies demonstrated that MVD was associated with worse prognosis compared to SVD patients [10, 33]. In this study, the in-hospital and 30-days MACE rates were similarly low in SVD group and MVD group (in-hospital MACE rate was both 0.0% in SVD and MVD groups and the 30-day MACE rate was 0.0% in SVD group and 1% in MVD group). During the short-term follow-up, there was no record on recurrent MI and stroke in young ACS patients. As expected, the rate of MACE rate was significantly higher in MVD group (20.2%, 18 repeat PCI and 3 CABG) than in SVD group (4.8%, 4 repeat PCI, p=0.002). It is to note that the relatively low in-hospital and 30-day MACE rate as well as the low MACE rate during the short-term follow-up period from patients in this cohort might be partly due to the use of new-generation drug-eluting stents. Recent studies suggested that stent thrombosis is less frequent with newer drug-eluting stents as compared to bare metal stents [34–36].

5. Limitations

The current study has several limitations. First, it was a retrospective and nonrandomized single-center study and caution is thus needed to extrapolate present study results to general young ACS and MVD population. Second, the relatively small patient cohort number serves as another study limitation. Third, there was no young female ACS patient in this cohort; this might relate to lower prevalence of ACS in young female population in our region; there is also no diabetic patient in our patient cohort. Therefore, our results could not be used to evaluate the contributing impact of diabetes and female gender on the pathogenesis of ACS and coronary vessel lesion, as well as outcome in young adults. Nevertheless, our patients are consecutive homogeneous unselected young patients with ACS; therefore, our data might exactly mirror the real-world scenario of young ACS as well as MVD patients in our region.

6. Conclusions

Hypertension serves as an independent risk factor of MVD and related to higher MACE rate during the short-term follow-up (death, repeat PCI, and CABG) in young male adults with ACS. Our results thus highlight the role of hypertension in the pathogenesis of MVD in young male ACS patients, indicating that rigorous hypertension control might be an important strategy for the prevention and treatment of MVD in young male ACS patients.

Data Availability

The data used to support the findings of this study are included within the article. The other data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors report no conflicts of interest.

Authors’ Contributions

Junhua Ge and Jian Li contributed equally to this work.
Acknowledgments

This work was supported by research grants from the National Natural Science Foundation of China [NSFC 81202002] and Applied Basic Research Foundation of Qingdao Science and Technology Bureau [Grant no. 16-5-1-57-jch].

References

[1] E. C. Leifheit-Limson, G. D’Onofrio, M. Daneshvar et al., “Sex differences in cardiac risk factors, perceived risk, and health care provider discussion of risk and risk modification among young patients with acute myocardial infarction: the VIRGO study,” Journal of the American College of Cardiology, vol. 66, no. 18, pp. 1949–1957, 2015.

[2] F. K. Hoo, Y. L. Foo, S. M. S. Lim, S. M. Ching, and Y. L. Boo, “Acute coronary syndrome in young adults from a Malaysian tertiary care centre,” Pakistan Journal of Medical Sciences, vol. 32, no. 4, pp. 841–845, 2016.

[3] M. Davis, J. Diamond, D. Montgomery, S. Krishnan, K. Eagle, and E. Jackson, “Acute coronary syndrome in young women under 55 years of age: clinical characteristics, treatment, and outcomes,” Clinical Research in Cardiology, vol. 104, no. 8, pp. 648–655, 2015.

[4] M. R. Esteban, S. M. Montero, J. J. Sánchez et al., “Acute Coronary Syndrome in the Young: Clinical Characteristics, Risk Factors and Prognosis,” The Open Cardiovascular Medicine Journal, vol. 8, no. 1, pp. 61–67, 2014.

[5] M. Doughty, R. Mehta, D. Bruckman et al., “Acute myocardial infarction in the young - The University of Michigan experience,” American Heart Journal, vol. 143, no. 1, pp. 56–62, 2002.

[6] A. Avezum, M. Makedsye, F. Spencer et al., “Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE),” American Heart Journal, vol. 149, no. 1, pp. 67–73, 2005.

[7] G. Jamil, M. Jamil, H. AlKhazzar et al., “Risk factor assessment of young patients with acute myocardial infarction,” American Journal of Cardiovascular Disease, vol. 3, no. 3, pp. 170–174, 2013.

[8] P. Widimsky and D. R. Holmes Jr., “How to treat patients with ST-elevation acute myocardial infraction and multi-vessel disease?” European Heart Journal, vol. 32, no. 4, pp. 396–403, 2011.

[9] P. Sardar, S. Chatterjee, J. Giri et al., “Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials,” International Journal of Cardiology, vol. 179, pp. 225–227, 2015.

[10] F. Ribichini, M. Romano, R. Rosiello et al., “A clinical and angiographic study of the XIENCE v everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: The executive trial (executive RCT: Evaluating XIENCE v in a multi vessel disease),” JACC: Cardiovascular Interventions, vol. 6, no. 10, pp. 1012–1022, 2013.

[11] M. Hamza and J. Y. Elgendy, “A Randomized Trial of Complete Versus Culprit-Only Revascularization during Primary Percutaneous Coronary Intervention in Diabetic Patients with Acute ST Elevation Myocardial Infarction and Multi Vessel Disease,” Journal of Interventional Cardiology, vol. 29, no. 3, pp. 241–247, 2016.

[12] J. T. Efird, W. T. O’Neal, S. W. Davies et al., “Long-Term Mortality of 306,868 Patients with Multi-Vessel Coronary Artery Disease: CABG versus PCI,” British Journal of Medicine and Medical Research, vol. 3, no. 4, pp. 1248–1257, 2013.

[13] R. Kreck, J. Drozdz, and M. Krzeminska-Pakula, “Prognostic factors in patients with advanced multi-vessel coronary artery disease,” Kardiolgia Polska, vol. 64, no. 11, pp. 1179–1185, 2006.

[14] J. L. Anderson, C. D. Adams, and E. M. Antman, “2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 127, no. 23, pp. e663–e828, 2013.

[15] J. D. Wessler, J. Stant, S. Duru, L. Rabbani, and A. J. Kirtane, “Updates to the ACCF/AHA and ESC STEMI and NSTEMI guidelines: Putting guidelines into clinical practice,” American Journal of Cardiology, vol. 115, no. 5, pp. 23–28, 2015.

[16] J. K. Min, D. S. Berman, A. Dunning et al., “All-cause mortality benefit of coronary revascularization vs. medical therapy in patients without known coronary artery disease undergoing coronary computed tomographic angiography: results from CONFIRM (CORonary Angiography Evaluation Of Clinical Outcomes: An IntErNational Multicenter Registry),” European Heart Journal, vol. 33, no. 24, pp. 3088–3097, 2012.

[17] M. H. Shishehbor, M. S. Lauer, I. M. Singh et al., “In Unstable Angina or Non-ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?” Journal of the American College of Cardiology, vol. 49, no. 8, pp. 849–854, 2007.

[18] N. Galié, M. Humbert, J.-L. Vachiery et al., “2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the european respiratory society (ERS): Endorsed by: Association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT),” European Heart Journal, vol. 37, no. 1, pp. 67–119, 2016.

[19] P. Arnold, D. Scheurer, A. W. Dake et al., “Hospital Guidelines for Diabetes Management and the Joint Commission-American Diabetes Association Inpatient Diabetes Certification,” The American Journal of the Medical Sciences, vol. 351, no. 4, pp. 333–341, 2016.

[20] N. J. Stone, J. G. Robinson, A. H. Lichtenstein et al., “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 129, no. 23, pp. S1–545, 2014.

[21] G. Montalescot, U. Sechtem, S. Achenbach et al., “2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology,” European Heart Journal, vol. 34, no. 38, pp. 2949–3003, 2013.

[22] E. Maor, P. Fefer, D. Varon et al., “Thrombophilic state in young patients with acute myocardial infarction,” Journal of Thrombosis and Thrombolysis, vol. 39, no. 4, pp. 474–480, 2015.

[23] Y. Lu, S. Zhou, R. P. Dreyer et al., “Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study,” American Heart Journal, vol. 183, pp. 74–84, 2017.

[24] K. S. Rathod, D. A. Jones, S. Gallagher et al., “Atypical risk factor profile and excellent long-term outcomes of young patients..."
treated with primary percutaneous coronary intervention for ST-elevation myocardial infarction,” *European Heart Journal: Acute Cardiovascular Care*, vol. 5, no. 1, pp. 23–32, 2016.

[25] A. H. Al-Khadra, “Clinical profile of young patients with acute myocardial infarction in Saudi Arabia,” *International Journal of Cardiology*, vol. 91, no. 1, pp. 9–13, 2003.

[26] S. Bajaj, F. Shamoon, N. Gupta et al., “Acute ST-segment elevation myocardial infarction in young adults: Who is at risk?” *Coronary Artery Disease*, vol. 22, no. 4, pp. 238–244, 2011.

[27] R. Sukhija, W. S. Aronow, D. Nayak, C. Ahn, and M. B. Weiss, “Increased fasting plasma insulin concentrations are associated with the severity of angiographic coronary artery disease,” *Angiology*, vol. 56, no. 3, pp. 249–251, 2005.

[28] A. F. Zand Parsa, H. Ziai, and L. Haghighi, “The impact of cardiovascular risk factors on the site and extent of coronary artery disease,” *Cardiovascular Journal of Africa*, vol. 23, no. 4, pp. 197–199, 2012.

[29] N. Buljubasic, K. M. Akkerhuis, S. P. de Boer et al., “Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound,” *PLoS ONE*, vol. 10, no. 10, Article ID e0141093, 2015.

[30] M. Yano, S.-I. Miura, Y. Shiga et al., “Association between smoking habits and severity of coronary stenosis as assessed by coronary computed tomography angiography,” *Heart and Vessels*, vol. 31, no. 7, pp. 1061–1068, 2016.

[31] A. Aggarwal, S. Srivastava, and M. Velmurugan, “Newer perspectives of coronary artery disease in young,” *World Journal of Cardiology*, vol. 8, no. 12, pp. 728–734, 2016.

[32] F. H. Zimmerman, A. Cameron, L. D. Fisher, and N. Grace, “Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (coronary artery surgery study registry),” *Journal of the American College of Cardiology*, vol. 26, no. 3, pp. 654–661, 1995.

[33] F. Ribichini and D. Taggart, “Implications of new ESC/EACTS guidelines on myocardial revascularisation for patients with multi-vessel coronary artery disease,” *European Journal of Cardio-Thoracic Surgery*, vol. 39, no. 5, pp. 619–622, 2011.

[34] M. Valgimigli, A. Patialiakas, A. Thury et al., “Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates,” *Journal of the American College of Cardiology*, vol. 65, no. 8, pp. 805–815, 2015.

[35] P. Urban, I. T. Meredith, A. Abizaid et al., “Polymer-free drug-coated coronary stents in patients at high bleeding risk,” *The New England Journal of Medicine*, vol. 373, no. 21, pp. 2038–2047, 2015.

[36] K. H. Bønaa, J. Mannsverk, R. Wiseth et al., “Drug-eluting or bare-metal stents for coronary artery disease,” *The New England Journal of Medicine*, vol. 375, no. 13, pp. 1242–1252, 2016.